Cannabis for Migraine: CB1, CGRP & Studies
- THC inhibits CGRP – the same target as migraine biologics (Aimovig, Emgality)
- Rhyne 2016 (n=121): −56 % reduction in migraine frequency with medical cannabis
- CECD Hypothesis: Migraine could be an Endocannabinoid Deficiency Syndrome (Russo 2004)
Migraine and the Endocannabinoid System
Migraine is one of the most common neurological disorders worldwide – about 15 percent of the population in Germany suffer from it. The Endocannabinoid System (ECS) plays a central role in pain modulation and neurotransmitter regulation, which are crucial in migraine pathogenesis.
CB1 receptors are found in high density in the trigeminovascular system – the core pathway of migraine physiology. The trigeminal neuropeptide CGRP (Calcitonin Gene-Related Peptide) is the most important vasodilatory mediator of migraine attacks: THC and other cannabinoids inhibit CGRP release from trigeminal nerve endings via CB1 activation, which directly exerts antinociceptive effects.
In addition, the ECS modulates serotonin release (similar to triptans), dampens the cortical spreading depression (CSD) – the electrophysiological origin of the migraine aura – and regulates central sensitization in the trigeminal nucleus caudalis.
Clinical Study Overview
| Study | Design | Result |
|---|---|---|
| Rhyne et al. 2016 (Pharmacotherapy) | Retrospective, n=121 migraine patients, medical cannabis | Migraine frequency decreased from 10.4 to 4.6/month (−56 %); 85 % reduction in acute attacks |
| Aviram & Samuelly-Leichtag 2020 (J Pain Res) | Prospective, n=145, inhalation/oil | Migraine: −55.5 % intensity; Pain in general: −64 %; Side effects 12 % |
| Baron 2018 (Headache) | Review, medical evidence status | Endocannabinoid Deficiency Theory (CECD) as a possible migraine mechanism |
| Pini et al. 2012 (Neurol Sci) | THC/CBD oral, n=48 chronic migraine | THC 200 mg/day: Pain reduction similar to Amitriptyline 25 mg/day; better tolerability |
CECD: Endocannabinoid Deficiency in Migraine
Ethan Russo coined the hypothesis of Clinical Endocannabinoid Deficiency (CECD) in 2016: In chronic migraine, fibromyalgia, and irritable bowel syndrome, anandamide levels in the cerebrospinal fluid are reduced. These three diseases share a common pathophysiology of central sensitization and tone regulation – and all three respond empirically to cannabinoids.
Anandamide inhibits trigeminal activation: Exogenous cannabinoids such as THC could compensate for this deficiency, which would explain the clinical observation that cannabis reduces attack frequency more in chronic migraine patients than in those with episodic migraine.
THC vs. CBD: Different Mechanisms of Action
THC (Acute Use): CB1 agonism directly inhibits CGRP and Substance P, reduces neurogenic inflammation, suppresses nausea via CB1 in the chemoreceptor trigger zone. Onset of action with inhalation is 5–10 minutes – relevant for the acute phase.
CBD (Prevention): FAAH inhibition → increase in anandamide; 5-HT1A agonism (similar to triptans); TRPV1 desensitization dampens nociceptive afferents; GPR55 antagonism inhibits CSD propagation. CBD acts more preventively than acutely.
Entourage Effect: The 1:1 ratio of THC/CBD (as in Sativex) shows better tolerability in studies than pure THC – CBD mitigates THC-induced anxiety and may exert additional migraine-specific effects through adenosine reuptake inhibition.
Practical Application and Dosage
Application: Inhalation (vaporizer, 170–185°C) allows for the fastest onset of effect. 1–2 puffs of THC-rich strain (>15 % THC, Myrcene/Linalool terpene profile) at the beginning of prodromes or aura. Early application is crucial – once the full pain has developed, effectiveness decreases.
Prevention: CBD oil 25–75 mg daily (sublingual administration), possibly supplemented with low-dose THC in the evening (0.5–2.5 mg). Study data show onset of effect after 4–8 weeks of continuous use.
Health insurance reimbursement: Migraine is recognized as an indication for medical cannabis if conventional therapies (beta blockers, topiramate, CGRP antibodies) have failed. The application is made by a neurologist with access to a pain clinic.
Contraindications and risks
Cannabis-induced Headache (Rebound): Chronic high-frequency cannabis use can paradoxically lead to an increase in the frequency of headaches – analogous mechanism to medication overuse headache (MOH). The threshold is empirically set at more than 15 consumption days per month.
Trigger risk: Smoking cannabis (cigarette) can act as a migraine trigger through hypoxia and carbon monoxide – vaporizers completely bypass this problem.
Interactions: Cannabis and triptans jointly influence the serotonergic tone; increased sedation risk is possible when combined. CYP interactions with valproate/topiramate (CYP2C19) must be strictly observed.
FAQ: Cannabis for Migraine
Zusammenfassung
Cannabis inhibits CGRP release in migraine via CB1, modulates serotonin similarly to triptans, and can compensate for the postulated endocannabinoid deficiency in chronic migraine. Clinical data show attack reductions of 40–56 percent. THC is suitable for acute treatment, CBD more for prevention. Chronic high consumption can lead to rebound headaches. GKV reimbursement is possible in cases of treatment resistance.
Cannabis for Crohn's disease: CBD, remission & studies
Cannabis for restless legs: CBD, dopamine & studies
Cannabis & bones: CB2, osteoporosis & bone healing
Cannabis & testosterone: effect on male fertility
Cannabis quality: laboratory tests, pesticides & contamination
Home cannabis cultivation: rules according to CanG
Leave a Reply
Want to join the discussion?Feel free to contribute!